

## Press Release

---

# Nicox: Implementation of a liquidity contract with Kepler Cheuvreux

---

August 5, 2020 – release at 7:30 am CET  
Sophia Antipolis, France

**Nicox SA** (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced today that it will implement a liquidity contract with Kepler Cheuvreux, effective as of August 5, 2020, with respect to Nicox shares listed on Euronext Paris.

The implementation of this liquidity contract, pursuant to the authorization granted by the fifth resolution of the ordinary shareholder meeting of June 16, 2020, will be carried out in accordance with the legal provisions in force and, more specifically, with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on market abuse (MAR); the delegated Commission Regulation (EU) 2016/908 of February 26, 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regulatory technical standards concerning the criteria, procedure and requirements for establishing an accepted market practice and the requirements for maintaining, withdrawing or amending the conditions for admission; and Articles L. 225-209 et seq. of the French Commercial Code, and the AMF decision no. 2018-01 of July 2, 2018, applicable as of January 1, 2019.

The following resources have been allocated to the liquidity account:

- the sum of 500,000 Euros (which may be increased up to 1,000,000 Euros)

The execution of the liquidity contract may be suspended under the conditions described in Article 5 of AMF decision no. 2018-01 of July 2, 2018.

The execution of the liquidity contract may also be suspended in the following circumstances:

- by Nicox, in the event that Kepler Cheuvreux has not made reasonable efforts to meet its obligations with respect to the liquidity of transactions and the regularity of quotations
- by Kepler Cheuvreux, when the information provided by the client makes it impossible for Kepler Cheuvreux to meet its obligations
- by Kepler Cheuvreux, when the sums due to Kepler Cheuvreux under the liquidity contract have not been paid on the payment date as stated in the invoice provided by Kepler Cheuvreux, and

The liquidity contract may be terminated subject to the following conditions:

- at any time by Nicox, subject to two (2) business days' notice
- at any time by Kepler Cheuvreux subject to thirty (30) calendar days' notice
- without notice and without formality if the shares are transferred to another stock market

### About Nicox

---

Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone,

for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch & Lomb, and ZERVIAE™ in allergic conjunctivitis, licensed in multiple geographies, including to EyeVance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: [www.nicox.com](http://www.nicox.com).

### Analyst coverage

Bryan, Garnier & Co	Victor Floc'h	Paris, France
Cantor Fitzgerald	Louise Chen	New York, U.S.
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Oppenheimer & Co	Hartaj Singh	New York, U.S.



*The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.*

### Contacts

#### Nicox

Gavin Spencer  
Executive Vice President, Chief Business Officer  
& Head of Corporate Development  
T +33 (0)4 97 24 53 00  
[communications@nicox.com](mailto:communications@nicox.com)

#### Investors & Media

United States & Europe  
LifeSci Advisors, LLC  
Hans Herklots  
T +41 79 598 71 49  
[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

#### Media

France  
LifeSci Advisors, LLC  
Sophie Baumont  
M +33 (0)6 27 74 74 49  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

### Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3<sup>rd</sup> chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox's website ([www.nicox.com](http://www.nicox.com)).

#### Nicox S.A.

Drakkar 2  
Bât D, 2405 route des Dolines  
CS 10313, Sophia Antipolis  
06560 Valbonne, France  
T +33 (0)4 97 24 53 00  
F +33 (0)4 97 24 53 99